|Bid||4.9600 x 1100|
|Ask||4.9300 x 1100|
|Day's Range||4.8600 - 5.2100|
|52 Week Range||4.7800 - 15.6000|
|Beta (5Y Monthly)||1.88|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 04, 2021 - Aug 09, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.00|
Accelerate Diagnostics, Inc. ( NASDAQ:AXDX ) shareholders (or potential shareholders) will be happy to see that the...
Some stocks are best avoided. We don't wish catastrophic capital loss on anyone. Spare a thought for those who held...
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) today announced the publication of its Improving Outcomes and Antibiotic Stewardship (IOAS) Study in the journal Clinical Infectious Diseases. The multi-center, real-world study compared data before and after implementation of the Accelerate Pheno system across several hospitals to determine its impact on the treatment of patients with bloodstream infections. The data showed statistically significant reductions in time to optimal antimicrobial therapy,